Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 7/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.44 |
| ▸ | RAF1 | P04049 | 7/20 | 0.43 |
| ▸ | BRAF | P15056 | 7/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14349115 | 0.87 | MCHR1 (0.46) | TACR1KDM4EGAAMCHR1RAF1 | |
| SCHEMBL4658238 | 0.84 | KDM4E (0.47) | KDM4EGAAMEN1RAB9AKMT2A | |
| SCHEMBL4660444 | 0.83 | TACR1 (0.67) | TACR1 | |
| SCHEMBL14349132 | 0.83 | TACR1 (0.55) | TACR1KDM4EMCHR1RAF1BRAF | |
| SCHEMBL4659141 | 0.83 | MCHR1 (0.42) | TACR1KDM4EGAAMCHR1MEN1 | |
| SCHEMBL14349114 | 0.82 | TACR1 (0.44) | TACR1MCHR1 | |
| SCHEMBL4763880 | 0.81 | MET (0.42) | TACR1KDM4EGAAMCHR1RAF1 | |
| SCHEMBL1399432 | 0.81 | TACR1 (0.70) | TACR1RAF1BRAF | |
| SCHEMBL14349117 | 0.78 | TACR1 (0.52) | TACR1BRAF | |
| SCHEMBL14349112 | 0.77 | TACR1 (0.48) | TACR1KDM4EGAAMCHR1RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1819342-A4 | QUINOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070293492-A1 | Quinoline Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2007-12-20 | — | — | US | disclosed |
| EP-1819342-A1 | QUINOLINE TACHYKININ RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006060390-A1 | QUINOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293492-A1 | Quinoline Tachykinin Receptor Antagonists | TACR1, TACR2, NPSR1 | TACR1 1/4885KDM4E 2973/4885GAA 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.